Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

What Sent These Five Stocks Lower on Monday?

Page 1 of 2

The US stock market started the last trading week of 2015 on a slightly negative note, with major indices losing ground on Monday. Among thousands of stocks,  Valeant Pharmaceuticals Intl Inc (NYSE:VRX), Chimerix Inc (NASDAQ:CMRX), Iconix Brand Group Inc (NASDAQ:ICON), Chesapeake Energy Corporation (NYSE:CHK), and Freeport-McMoRan Inc (NYSE:FCX) have depreciated significantly on the back of different events. Let’s take a closer look at the developments that sent these stocks lower on Monday and see what the funds from our database think about them.

At Insider Monkey, we track over 730 hedge funds and other institutional investors. By analyzing their quarterly 13F filings we determine the stocks that they are collectively bullish on, which allows us to mimic some of these picks and beat the market. Our focus is the small-cap picks of the investors we track and by imitating the 15 most popular small-cap stocks among these funds we have managed to generate returns of around 102% since August 2012, outperforming the S&P 500 ETF (SPY) by some 53 percentage points (see more details here).

Let’s start with Valeant Pharmaceuticals Intl Inc (NYSE:VRX), whose stock is down by around 10% after news that its CEO Michael Pearson was hospitalized due to pneumonia. A group of executives will take Pearson’s role until he recovers, the company said. Today’s drop ended several days of gains that slightly offset the losses registered in the past several months. In this way, Valeant Pharmaceuticals Intl Inc (NYSE:VRX)’s stock is down by more than 50% in the last six months and has lost 28% since the beginning of the year. Despite the decline registered by the stock, most smart money investors remain optimistic about Valeant Pharmaceuticals Intl Inc (NYSE:VRX) that has also two activists among its top shareholders. Bill Ackman‘s Pershing Square and Jeff Ubben’s ValueAct Capital are two of the 88 funds from our database that are long Valeant as of the end of September, down by 98 funds a quarter earlier.

Follow Valeant Pharmaceuticals International Inc. (NYSE:VRX)
Trade (NYSE:VRX) Now!

Then there is Chimerix Inc (NASDAQ:CMRX), whose shares are over 80% in the red on the back of the disappointing results of Phase 3 trial SUPPRESS its oral antiviral drug brincidofovir that was tested in patients undergoing hematopoietic cell transplantation. According to the company, brincidofovir did not manage to achieve the primary endpoint for the prevention of cytomegalovirus infection (a member of the herpes virus family) in 24 weeks since the transplant.

“Preliminary analysis suggests that the primary endpoint failures in both the prevention of CMV infections and mortality in the brincidofovir arm were driven by confirmed cases of graft-versus-host-disease (GVHD),” the company said in a statement.

Among the funds we follow, Chimerix Inc (NASDAQ:CMRX) is not very popular with only 17 funds reporting long positions in the last round of 13F filings, amassing around 12% of its outstanding stock. Healthcare-focused funds Jeremy Green’s Redmile Group and Samuel Isaly’s OrbiMed Advisors are among the company’s top shareholders, owning 1.07 million shares and 1.02 million shares, respectively.

Follow Chimerix Inc (NASDAQ:CMRX)
Trade (NASDAQ:CMRX) Now!

On the next page, we are going to discuss what led to the decline of the other three stocks.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!